Selective Estrogen Receptor Modulators (SERMS)
, by Nih Workshop on Selective Estrogen Receptor Modulators (Serms) (2000; Dunn, Barbara K.; Sherman, Sherry; Anthony, Marietta; Anthony, Marietta; Dunn, Barbara K.; Sherman, Sherry- ISBN: 9781573313599 | 1573313599
- Cover: Paperback
- Copyright: 10/1/2001
Preface | p. xi |
Basic Biology of SERMs | |
The Basic Biology of SERMs: Introduction | p. 1 |
Nuclear Receptors, Coregulators, Ligands, and Selective Receptor Modulators: Making Sense of the Patchwork Quilt | p. 3 |
Structure-Function Relationships in Estrogen Receptors and the Characterization of Novel Selective Estrogen Receptor Modulators with Unique Pharmacological Profiles | p. 6 |
Capitalizing on the Complexities of Estrogen Receptor Pharmacology in the Quest for the Perfect SERM | p. 16 |
Developing Animal Models for Analyzing SERM Activity | p. 36 |
Androgen Receptor: Structural Domains and Functional Dynamics after Ligand-Receptor Interaction | p. 44 |
Tissue-Specific Estrogen Biosynthesis and Metabolism | p. 58 |
Cancer Treatment and Prevention | |
Cancer Treatment and Prevention: Introduction | p. 68 |
The Past, Present, and Future of Selective Estrogen Receptor Modulation | p. 72 |
Use of SERMs for the Adjuvant Therapy of Early-Stage Breast Cancer | p. 80 |
Breast Cancer Prevention with Selective Estrogen Receptor Modulators: A Perspective | p. 89 |
The Role of Tamoxifen in Breast Cancer Prevention: Issues Sparked by the NSABP Breast Cancer Prevention Trial (P-1) | p. 99 |
The Royal Marsden Hospital (RMH) Trial: Key Points and Remaining Questions | p. 109 |
The Italian Breast Cancer Prevention Trial with Tamoxifen: Findings and New Perspectives | p. 113 |
A Brief Review of the International Breast Cancer Intervention Study (IBIS), the Other Current Breast Cancer Prevention Trials, and Proposals for Future Trials | p. 123 |
The MORE Trial--Multiple Outcomes for Raloxifene Evaluation: Breast Cancer as a Secondary End Point--Implications for Prevention | p. 134 |
Quality of Life and Tamoxifen in a Breast Cancer Prevention Trial: A Summary of Findings from the NSABP P-1 Study | p. 143 |
Cardiovascular Disease | |
Selective Estrogen Receptor Modulators and Cardiovascular Disease: Introduction | p. 151 |
Cardiovascular Trials of Estrogen Replacement Therapy | p. 153 |
The Effects of Estrogen and Selective Estrogen Receptor Modulators on Cardiovascular Risk Factors | p. 163 |
Selective Estrogen Receptor Modulator Effects on Serum Lipoproteins and Vascular Function in Postmenopausal Women and in Hypercholesterolemic Men | p. 168 |
Effects of Estrogen and Selective Estrogen Receptor Modulators on Hemostasis and Inflammation: Potential Differences among Drugs | p. 175 |
Rationale and Overview of the Raloxifene Use for the Heart (RUTH) Trial | p. 181 |
Osteoporosis | |
Prevention and Treatment of Osteoporosis: Introduction | p. 186 |
Preventing and Treating Osteoporosis: Strategies at the Millennium | p. 188 |
The Paradox of Small Changes in Bone Density and Reductions in Risk of Fracture with Raloxifene | p. 198 |
Cognitive Function | |
SERMs, Estrogen, and Cognitive Function: Introduction | p. 202 |
Effects of Hormone Replacement Therapy on Cognitive and Brain Aging | p. 203 |
Estrogens, Selective Estrogen Receptor Modulators, and Dementia: What Is the Evidence? | p. 215 |
Estrogen Replacement Therapy for the Potential Treatment or Prevention of Alzheimer's Disease | p. 223 |
Reproductive and Related Endocrine Considerations | |
Reproductive and Related Endocrine Considerations: Introduction | p. 235 |
The Effect of SERMs on the Endometrium | p. 237 |
Effect of Selective Estrogen Receptor Modulators on Reproductive Tissues Other Than Endometrium | p. 243 |
The Effect of Selective Estrogen Receptor Modulators on Parameters of the Hypothalamic-Pituitary-Gonadal Axis | p. 251 |
Addressing the Benefit/Risk Ratio in Taking SERMs from Laboratory to Clinic | |
Translation of Basic Research--Finding the Perfect SERM: Introduction | p. 259 |
What Would Be the Properties of an Ideal SERM? | p. 261 |
Weighing the Benefits and Risks in Clinical Trials and Practice: Introduction | p. 279 |
Benefit/Risk Assessment of SERM Therapy: Clinical Trial versus Clinical Practice Settings | p. 280 |
The Estimation and Use of Absolute Risk for Weighing the Risks and Benefits of Selective Estrogen Receptor Modulators for Preventing Breast Cancer | p. 286 |
SERMs, Ethnicity, and Clinical Trials: Opportunities and Challenges | p. 292 |
Raloxifene: Risks and Benefits | p. 295 |
Defining Benefits and Risks for SERMs in Clinical Trials and Clinical Practice | p. 304 |
SERM Development in Industry, Academia, the NIH, and the FDA | |
Roles of Industry, Government, and Academia in SERM Development: Introduction | p. 315 |
Developing a SERM: Stringent Preclinical Selection Criteria Leading to an Acceptable Candidate (WAY-140424) for Clinical Evaluation | p. 317 |
The Breast Cancer Continuum: Insights from the Tamoxifen Trials Impact Future Drug Development Strategies | p. 327 |
The Cancer Therapy Evaluation Program (CTEP) at the National Cancer Institute: Industry Collaborations in New Agent Development | p. 333 |
FDA Review Practices and Priorities for Drugs Used in Cancer Treatment | p. 341 |
Tamoxifen for the Reduction in the Incidence of Breast Cancer in Women at High Risk for Breast Cancer | p. 345 |
Negotiating Industry-Sponsored Clinical Trial Agreements: A View from the Trenches | p. 349 |
Conclusions: Considerations Regarding SERMs | p. 352 |
Opportunites for Future Research | p. 366 |
Everything You Wanted to Know about SERMs | |
Timeline of Key Events in SERM Development | p. 377 |
Estrogen Receptor-Active Compounds, Estrogens, and SERMs, of Historical and Current Interest | p. 381 |
Model of Estrogen Receptor (ER) Action | p. 382 |
Action of SERMs in Target Tissues | p. 383 |
Glossary of Abbreviations | p. 385 |
Index of Contributors | p. 389 |
Table of Contents provided by Syndetics. All Rights Reserved. |
What is included with this book?
The New copy of this book will include any supplemental materials advertised. Please check the title of the book to determine if it should include any access cards, study guides, lab manuals, CDs, etc.
The Used, Rental and eBook copies of this book are not guaranteed to include any supplemental materials. Typically, only the book itself is included. This is true even if the title states it includes any access cards, study guides, lab manuals, CDs, etc.